Animab

Animab is a Belgian biotechnology company that develops monoclonal antibodies to improve livestock health and performance. It specializes in orally administered antibodies that mimic secretory IgA, which is naturally passed through colostrum and milk to protect nursing animals. These proprietary antibodies are designed to safeguard piglets' intestinal health during the critical post-weaning stage, targeting specific pathogens without disrupting the healthy microbiome​.

Animab’s proprietary platform creates synthetic monoclonal antibodies that not only target immediate pathogenic threats but also open avenues for addressing a wide range of gastrointestinal conditions across various livestock species. This technology minimizes the need for traditional antibiotics and provides an alternative to zinc oxide, which was banned as of 2022 due to environmental concerns. 

Key customers and partnerships

Animab collaborates closely with leading academic institutions like VIB and Ghent University to refine its antibody technologies and enhance its product offerings, ensuring high precision in pathogen targeting.

Funding and financials

In its latest funding round in November 2022, Animab raised EUR 10 million (~USD 10.8 million) in Series A funding led by Qbic III, with participation from Seventure Partners, VIB, PMV, AIF, and V-Bio Ventures. The funding was earmarked for the commercialization of its lead product and expansion of its pipeline.